Epstein Secrets

less $100,000) with Robert. How much did Sean make on the trades? ZERO dollars. He had no idea that Cunniffe traded because he did not even know who Cunniffe was. It was a clear case of misappropriation where information was used without Sean's knowledge, so it was not a "classical" insider trading case.

dollars on the trades, sharing a small amount (less $100,000) with Robert. How much did Sean make on the trades? ZERO dollars. He had no idea that Cunniffe traded because he did not even know who Cunniffe was. It was a clear case of misappropriation where information was used without Sean's knowledge, s

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

less $100,000) with Robert. How much did Sean make on the trades? ZERO dollars. He had no idea that Cunniffe traded because he did not even know who Cunniffe was. It was a clear case of misappropriation where information was used without Sean's knowledge, so it was not a "classical" insider trading case.

dollars on the trades, sharing a small amount (less $100,000) with Robert. How much did Sean make on the trades? ZERO dollars. He had no idea that Cunniffe traded because he did not even know who Cunniffe was. It was a clear case of misappropriation where information was used without Sean's knowledge, s

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

n dollars on the trades, sharing a small amount (less $100,000) with Robert. How much did Sean make on the trades? ZERO dollars. He had no idea that Cunniffe traded because he did not even know who Cunniffe was. It was a clear case of misappropriation where information was used without Sean's knowledge,

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been